Targeted drug delivery across blood-brain-barrier using cell penetrating peptides tagged nanoparticles

Current Nanoscience

Volumn 7, Issue 1, 2011, Pages 81-93

  Malhotra, Meenakshi ^a   Prakash, Satya ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Blood brain barrier; Cell penetrating peptides; Multifunctionality; Nanocapsules; Nanomedicine; Nanotechnology; Polymeric nanoparticles; Targeted delivery

Indexed keywords

BLOOD-BRAIN BARRIER; CELL-PENETRATING PEPTIDE; MULTIFUNCTIONALITY; NANOMEDICINES; POLYMERIC NANOPARTICLES; TARGETED DELIVERY;

BLOOD; DRUG DELIVERY; FUNCTIONAL POLYMERS; GENE THERAPY; MEDICAL NANOTECHNOLOGY; NANOCAPSULES; PEPTIDES; POLYMERS; VIRUSES;

NANOPARTICLES;

CELL PENETRATING PEPTIDE; NANOCAPSULE; NANOCARRIER; NANOPARTICLE; PENETRATIN; POLYARGININE; TRANSACTIVATOR PROTEIN; TRANSPORTAN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; CYTOTOXICITY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG TRANSPORT; INTERSTITIUM; NANOTECHNOLOGY; PRIORITY JOURNAL;

EID: 79551659855     PISSN: 15734137     EISSN: None     Source Type: Journal    
DOI: 10.2174/157341311794480336     Document Type: Article

References (209)

1. Ballabh, P.; Braun, A.; Nedergaard, M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis., 2004, 16, 1-13.
2. Steuer, H.; Jaworski, A.; Stoll, D.; Schlosshauer, B. In vitro model of the outer blood-retina barrier. Brain Res. Brain Res. Proc., 2004, 13, 26-36.
3. Huber, J.D.; Egleton, R.D.; Davis, T.P. Molecular physiology and patho- physiology of tight junctions in the blood-brain barrier. Trends Neurosci., 2001, 24, 719-725.
4. Bazzoni, G.; Dejana, E. Endothelial cell to cell junctions: Molecular organi-zation and role in vascular homeostasis. Physiol. Rev., 2004, 84, 869-901.
5. W.M. Blood-brain barrier drug targeting: the future of brain drug development. Mol. Interv., 2003, 3, 90-105.
6. Pardridge, W.M. Drug and gene targeting to the brain with molecular Trojan horses. Nat. Rev. Drug Discov., 2002, 1, 131-139.
7. Tiwari, S.B.; Amiji, M.M. A review of nanocarrier-based CNS delivery systems. Curr. Drug Deliv., 2006, 3, 219-232.
8. Torchilin, V.P. Recent approachs to intracellular delivery of drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng., 2006, 8, 343-375.
9. Owens, D.E.; Peppas, N.A. Opsonization, biodistribution and pharmacoki-netics of polymeric nanoparticles. Int. J. Pharm., 2006, 307, 93-102.
10. Rubin, L.L.; Staddon, J.M. The cell biology of the blood-brain barrier. Annu. Rev. Neurosci., 1999, 22, 11-28.
11. Janzor, R.C.; Ranff, M.C. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature, 1987, 325, 253-257.
12. Gaillard, P.J.; Vander Sandt, I.C.; Voorwinden, L.H.; Vu, D.; Nielsen, J.L. Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier. Pharm. Res., 2000, 17, 1198-1205.
13. Lai, C.H., Kuo, K.H. The critical component to establish in vitro BBB model: Pericyte. Brain Res. Brain Res. Rev., 2005, 50, 258-265.
14. Brightman, M.W. B. In: Physiology and pharmacology of the blood-brain barrier, Brightman, M.W.B., Ed.; Springer: Berlin, 1992; Vol. 103, pp. 1-22.
15. Ciechanover, A. Proteolysis from the lysosome to ubiquitin and the protea- some. Nat. Rev. Mol. Cell Biol., 2005, 61, 79-87.
16. Smith, Q.R. In: Advances in neurology; Wurtman, R., Ed.; Alzheimer's disease, Raven Press: New York, 1990; Vol. 51, pp. 217-222.
17. Pardridge, W.M. Molecular biology of the blood-brain barrier. Mol. Biotech-nol., 2005, 30, 57-70.
18. Pardridge, W.M. In: Peptide drug Delivery to the Brain, Raven Press: New York, 1991; pp. 1-357.
19. Wolburg, H.; Risau, W. In: Neuroglia, Kettenmann, H.; Ransom, B.R., Eds.; Oxford University Press: New York, 1995; pp. 763-776.
20. Butte, A.M.; Jones, H.C.; Abott, N.J. Electrical resistance across the blood-brain barrier in anesthetised rats: a developmental study. J. Physiol., 1990, 429, 47-62.
21. Allt, G.; Lawrenson, J.G. Pericytes: cell biology and pathology. Cells Tissues Organs, 2001, 169, 1-11.
22. Bandopadhyay, R.; Orte, C.; Lawrenson, J.G.; Reid, A.R.; De Silva, S.; Allt, G. Contractile proteins in pericytes at the blood-brain and blood-retinal bar-riers. J. Neurocytol., 2001, 30, 35-44.
23. Lindahl, P.; Johansson, B.R.; Leveen, P.; Betsholtz, C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science, 1997, 277, 242-245.
24. Balabanov, R.; Dore-Duffy, P. Role of the CNS microvascular pericyte in the bloodbrain barrier. J. Neurosci. Res., 1998, 53, 637-644.
25. Bouldin, T.W.; Krigman, M.R. Differential permeability of cerebral capillary and choroid plexes to lanthanum ion. Brain Res., 1975, 99, 444-448.
26. Brightman, M.W. The intracerebral movement of proteins injected into blood and cerebrospinal fluid of mice. Prog. Brain Res., 1968, 29, 19-40.
27. Nabeshima, S.; Reese, T.S.; Landis, D.M.; Brightman, M.W. Junctions in the meninges and marginal glia. J. Comp. Neurol., 1975, 164, 127-169.
28. Pardridge, W.M. Drug delivery to the brain. J. Cereb. Blood Flow Metab., 1997, 17, 713-731.
29. Pardridge, W.M. Recent advances in blood-brain barrier transport. Annu. Rev. Pharmicol. Toxicol., 1988, 28, 25-39.
30. Ghersi-Egea, J.F.; Leininger-Muller, B.; Cecchelli, R.; Fenstermancher, J.D. Blood-brain interfaces: relevance to cerebral drug metabolism. Toxicol. Lett., 1995, 82, 645-653.
31. Boer, A.G.; Gaillard, P.J. Drug targeting to the brain. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 9.1-9.33.
32. Olivier, J.C. Drug transport to brain with targeted nanoparticles. NeuroRX, 2005, 2, 108-119.
33. Tusji, A. In: The blood-brain barrier and drug delivery to the CNS, Marcel Dekker Inc.: New York, NY 2000; pp. 121-144.
34. Schinkel, A.H. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Deliv. Rev., 1999, 36, 179-194.
35. E.M. The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin. Pharm. Kinet., 2002, 41, 81-92.
36. Bradbury, M.; Begley, D.J.; Kreuter, J.; (Eds): The Blood-Brain Barrier and Drug Delivery to the CNS. Informa Healthcare, USA 2000.
37. Loscher, W.; Potschka, H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRX, 2005, 2, 86-98.
38. Begley, D.J. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther., 2004, 104, 29-45.
39. Chen, Y.; Dalwadi, G.; Benson H.A.E. Drug delivery across the Blood-Brain Barrier. Curr. Drug Deliv., 2004, 1, 361-376.
40. ® block copolymers asmodulators of drug efflux transporter activity in the blood-brain barrier. Adv. Drug Deliv. Rev., 2003, 55, 151-164.
41. Sadeque, A.J.; Wandel, C.; He, H.; Shah, S.; Wood, A.J. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin. Pharmacol. Ther., 2000, 68, 231-237.
42. Salvolainen, J.; Edwards, J.E.; Morgan, M.E.; McNamara P.J.; Anderson, B.D. Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats. Drug Metab. Dispos., 2002, 30, 479-482.
43. Löscher, W.; Potschka, H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol., 2005, 76, 22-76.
44. Yaksh, T.L.; Provencher, J.C.; Rathbun, M.L.; Myers, R.R.; Powell, H.; Richter, P.; Kohn, F.R. Safety assessment of encapsulated morphine delivered epidurally in a sustained-release multivesicular liposome preparation in dogs. Drug Deliv., 2000, 7, 7-36.
45. Pardridge, W.M. The blood-brain barrier: bottleneck in brain drug develop-ment. NeuroRx, 2005, 2, 3-14.
46. Misra, A.; Ganesh, S.; Shrenik, P. Drug delivery to the central nervous system: a review. J. Pharm. Pharmaceut. Sci., 2003, 6, 252-273.
47. Bodor, N.; Buchwald, P. Recent advances in the brain targeting of neiro- pharmaceuticals by chemical delivery systems. Adv. Drug. Deliv. Rev., 1999, 36, 229-254.
48. S. Use of hypoxia directed drugs in the therapy of solid tumours. Semin. Oncol., 1992, 19, 29-40.
49. Risau, W. Molecular biology of blood-brain barrier ontogenesis and function. Acta. Neurochir., 1994, 60, 109-112.
50. Fung, L.K.; Ewend, M.G.; Sills, A.; Sipos, E.P.; Thompson, R.; Watts, M.; Colvin, O.M.; Brem, H.; Saltzman, W.M. Pharmacokinetics of interstitial delivery of carmustine, 4- hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res., 1998, 58, 672-684.
51. Abbott, N.J.; Romero, I.A. Transporting therapeutics across the blood-brain barrier. Mol. Med. Today, 1996, 2, 106-113.
52. Nutt, J.G.; Woodward, W.R.; Hammerstad, J.P.; Carter, M.N.; Anderson, J.L. The on-off mechanism in Parkinson's disease. Relation to levodopa absorption and transport. N. Engl. J. Med., 1984, 310, 483-488.
53. Herzog, C.D.; Dass, B.; Holden, J.E.; Stansell, J.; Gasmi, M.; Tuszynski, M.H.; Bartus, R.T.; Kordower, J.H. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of dopaminergic nigros-triatal system in aged monkeys. Mov. Disord., 2007, 22, 1124-1132.
54. Marks, W.J.; Ostrem, J.L.; Verhagen, L.; Starr, P.A.; Larson, P.S.; Bakay, R.A.E.; Taylor, R.; Cahn-Weiner, D.A.; Stoessel, A.J.; Olanow, C.W.; Bar-tus, R.T. Safety and tolerability of intraputaminal delivery of CERE-120 (adenovirus-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open label, phase I trial. Lancet Neurol., 2008, 7, 400-408.
55. Bobo, R.H.; Laske, D.W.; Akbasak, A.; Morrison, P.F.; Dedrick, R.L.; Oldfield, E.H. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. USA, 1994, 91, 2076-2082.
56. Vandergrift, W.A.; Patel, S.J.; Nicholas, J.S.; Varma, A.K. Convection-enhanced delivery of immunotoxins and radioisotopes for treatment of malignant gliomas. Neurosurg. Focus, 2006, 20, E10.
57. Carter, B.S.; Zervas, N.T.; Chiocca, E.A. Neurogenetic surgery: current limitations and the promise of gene- and virus-based therapies. Clin. Neuro- surg., 1999, 45, 226-246.
58. Shapiro, W.; Shapiro, J.; Walker, R.; Central nervous system. In: Abeloff, M.; Armitage, J.; Lichter, A.N.J. Eds, Clinical oncology. New York, Chur- chill Livingstone, 2000, 1103-1193.
59. Markowitz, D.C.; Fernstorm, J.D. Diet and uptake of Aldomet by the brain: competition with natural large neutral amino acids. Science, 1977, 197, 1014-1015.
60. Taylor, E.M. The impact of efflux transporters in the brain on the develop-ment of drugs for CNS disorders. Clin. Pharmacokinet., 2002, 14, 81-92.
61. VanBree, J.B.M.M.; Audus, K.L.; Borchardt, R.T. Carrier mediated transport of baclofen across monolayers of bovine brain endothelial cells in primary culture. Pharm. Res., 1988, 5, 369-371.
62. Pratt, O.E. In: Physiology and Pharmacology of the blood-brain barrier. Bradbury, M.W.B., Ed.; Springer-Verlag: Berlin, 1992, 205-220.
63. Thorne, R.G.; Frey, W.H. Delivery of neurotropic factor to the central nerv-ous system: pharmacokinetic consideration. Clin. Pharmacokinet., 2001, 40, 907-946.
64. Born, J.; Lange, T.; Kern, W. Sniffing neuropeptides: a transnasal approach to the human brain. Nat. Neurosci., 2002, 5, 514-516.
65. Illum, L. Nasal drug delivery: new development strategies. Drug Discov. Today, 2002, 7, 1184-1189.
66. Thorne, R.G.; Emory, C.R.; Ala, T.A.; Fery, W.H. Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res., 1995, 692, 278-282.
67. Dubin, C.H. Special delivery: pharmaceutical companies aim to target their drugs with nano precision. Mech. Eng. Nanotechnol., 2004, 126, 10-12.
68. Dass, C.R.; Su, T. Particle-mediated intravascular delivery of oligonucleo-tides to tumors, associated biology and lessons from genotherapy. Drug Deliv., 2001, 8, 191-213.
69. Kumar, M.N.V.R. Nano and Microparticles as controlled drug Delivery Devices. J. Pharm. Pharmaceut. Sci., 2000, 3, 234-258.
70. La Van. D.A.; McGuire, T.; Langer, R. Small-scale systems for in vivo drug delivery. Nat. Biotechnol., 2003, 21, 1184-1191.
71. Schiffelers, R.M.; Ansari, A.; Xu, J. Cancer siRNA therapy by tumor selec-tive delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res., 2004, 32, e149.
72. McNeil, S.E. Nanotechnology for the biologist. J. Leukoc. Biol., 2005, 78, 585-594.
73. Panyam, J.; Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev., 2003, 55, 329-347.
74. Panyam, J.; Dali, M.M.; Sahoo, S.K.; Ma, W.; Chakravarthi, S.S.; Amidon, G.L. Polymer degradation and in vitro release of a model protein from poly(d,l-lactide-co-glycolide) nano- and microparticles. J. Control. Release, 2003, 92, 173-187.
75. Nugent, J.; Wan Po, A.L.; Scott, E.M. Design and delivery of nonparenteral vaccines. J. Clin. Pharm. Ther., 1998, 23, 257-285.
76. Katare, Y.K.; Panda, A.K.; Lalwani, K.; Haque, I.U.; Ali, M.M. Potentiation of immune response from polymer-entrapped antigen: toward development of single dose tetanus toxoid vaccine. Drug Deliv., 2003, 10, 231-238.
77. Lee, K.E.; Kim, B.K.; Yuk, S.H. Biodegradable polymeric nanospheres formed by temperature-induced phase transition in a mixture of poly(lactide- co-glycolide) and poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymer. Biomacromolecules, 2002, 3, 1115-1119.
78. Brannon-Peppas, L.; Blanchette, J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev., 2004, 56, 1649-1659.
79. Rosiak, J.M.; Janik, I.; Kadlubowski, S.; Kozicki, M.; Kujawa, P.; Stasica, P. Nano-, micro- and macroscopic hydrogels synthesized by radiation tech- nique. Nucl. Instrum. Methods Phys. Res. B, 2003, 208, 325-330.
80. Ggiannavola, C.; Bucolo, C.; Maltese, A.; Paolino, D.; Vandelli, M.A.; Puglisi, G. Influence of preparation conditions on acyclovirloaded poly-d,l- lactic acid nanospheres and effect of PEG coating on ocular drug bioavail- ability. Pharm. Res., 2003, 20, 584-590.
81. Kompella, U.B.; Bandi, N.; Ayalasomayajula, S.P. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest. Ophthalmol. Visual Sci., 2003, 44, 1192-1201.
82. Sanchez, A.; Tobio, M.; Gonzalez, L.; Fabra, A.; Alonso, M.J. Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon- alpha. Eur. J. Pharm. Sci., 2003, 18, 221-229.
83. Salgueiro, A.; Gamisans, F.; Espina, M.; Alcober, X.; Garcia, M.L.; Egea, M.A. Cyclophosphamide-loaded nanospheres: analysis of the matrix structure by thermal and spectroscopic methods. J. Microencapsulation, 2002, 19, 305-310.
84. Piddubnyak, V.; Kurcok, P.; Matuszowicz, A.; Glowala, M.; Fiszer-Keirzkowska, A.; Jedlinski, Z. Oligo-3-hydroxybutyrates as potential carriers for drug delivery. Biomaterials, 2004, 25, 5271-5279.
85. Kim, J.I.; Jun, Y.J.; Seong, J.Y.; Jun, M.J.; Sohn, Y.S. Synthesis and charac-terization of nanosized poly(organophosphazenes) with methoxy- poly(ethylene glycol) and dipeptide ethyl esters as side groups. Polymer, 2004, 45, 7083-7089.
86. Moghimi, S.M. Capture of stealth nanoparticles by the body's defences. Crit. Rev. Ther. Drug Carrier Syst., 2001, 18, 527-550.
87. Kumar, R.; Ming-Hsiung, C.; Parmar, V.S.; Samuelson, L.A.; Kumar, J.; Nicolosi, R. Supramolecular assemblies based on copolymers of PEG600 and functionalized aromatic diesters for drug delivery applications. J. Am. Chem. Soc., 2004, 126, 10640-10644.
88. Vila, A.; Gill, H.; McCallion, O.; Alonso, M.J. Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density. J. Control. Release, 2004, 98, 231-244.
89. Luu, Y.K.; Kim, K.; Hsiao, B.S.; Chu, B.; Hadjiargyrou, M. Development of a nanostructured DNA delivery scaffold via electrospinning of PLGA and PLA-PEG block copolymers. J. Control. Release, 2003, 89, 341-353.
90. Zhang, L.; Hu, Y.; Jiang, X.; Yang, C.; Lu, W.; Yah, Y.H. Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone- co-lactide) nanoparticles and their biodistribution in mice. J. Control. Re-lease, 2004, 96, 135-148.
91. Rodrigues, J.S.; Santos-Magalhaes, N.S.; Coelho, L.C.B.B.; Couvreur, P.; Ponchel, G.; Gref, R. Novel core(polyester)-shell(polysaccharide) nanoparticles: protein loading and surface modification with lectins. J. Control. Re-lease, 2003, 92, 103-112.
92. Van Domeselaar, G.H.; Kwon, G.S.; Andrew, L.C.; Wishart, D.S. Applica-tion of solid phase peptide synthesis to engineering PEO peptide block co- polymers for drug delivery. Colloids Surfaces B Biointerfaces, 2003, 30, 323-334.
93. Panoyan, A.; Quesnel, R.; Hildgen, P. Injectable nanospheres from a novel multiblock copolymer: cytocompatibility, degradation and in vitro release studies. J. Microencapsul., 2003, 20, 745-758.
94. Otsuka, H.; Nagasaki, Y.; Kataoka, K. PEGylated nanoparticles for biologi-cal and pharmaceutical applications. Adv. Drug Deliv. Rev., 2003, 55, 403-419.
95. Lockman, P.R.; Koziara, J.M.; Mumper, R.J.; Allen, D.D. Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J. Drug Target, 2004, 12, 635-641.
96. J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev., 2001, 47, 65-81.
97. Labhasetwar, V.; Song, C.; Humphrey, W. Arterial uptake of biodegradable nanoparticles: effect of surface modifications. J. Pharm. Sci., 1998, 87, 1229-1234.
98. Ulrich, K.E.; Cannizzaro, S.M.; Langer, R.S.; Shakeshelf, K.M.; Polymeric systems for controlled drug release. Chem. Rev., 1999, 99, 3181-3198.
99. Singh, R.; James, W.; Lillard, J. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol., 2009, 86, 215-223.
100. Szentkuti, L. Light microscopical observations on luminally administered dyes, dextrans, nanospheres and microspheres in the pre-epithelial mucus gel layer of the rat distal colon. J. Control. Release, 1997, 46, 233-242.
101. Heydenreich, A.V.; Westmeier, R.; Pedersen, N. Preparation and purification of cationic solid lipid nanospheres-effects on particle size, physical stability and cell toxicity. Int. J. Pharm., 2003, 254, 83-87.
102. Dong, Y.; Feng, S.S. Methoxy poly(ethylene glycol)-poly(lactide) (MPEG- PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials, 2004, 25, 2843-2849.
103. Neradovic, D.; Soga, O.; Van Nostrum, C.F. The effect of the processing and formulation parameters on the size of nanoparticles based on block copolymers of poly(ethylene glycol) and poly(Nisopropylacrylamide) with and without hydrolytically sensitive groups. Biomaterials, 2004, 25, 2409-2418.
104. Fischer, D.; Li, Y.; Ahlemeyer, B. In vitro cytotoxicity testing of polyca-tions: influence of polymer structure on cell viability and haemolysis. Biomaterials, 2003, 24, 1121-1131.
105. Hawkins, B.T.; Davis, T.P. The Blood-Brain Barrier/Neurovascular Unit in Health and Disease. Pharmacol. Rev., 2005, 57, 173-185.
106. Beyerle, A.; Merkel, O.; Stoeger, T.; Kissel, T. PEGylation affects cytotoxic-ity and cell-compatibility of poly(ethylene imine) for lung application: structure function relationships. Toxicol. Appl. Pharmacol., 2010, 242, 146-154.
107. Stoeger, T.; Reinhard, C.; Takenaka, S.; Schroeppel, A.; Karg, E.; Ritter, B.; Heyder, J.; Schulz, H. Instillation of six different ultrafine carbon particles indicates a surface area threshold dose for acute lung inflammation in mice. Environ. Health Perspect., 2006, 114, 328-333.
108. Stoeger, T.; Takenaka, S.; Frankenberger, B.; Ritter, B.; Karg, E.; Maier, K.; Schulz, H.; Schmid, O. Deducing In vivo toxicity of combustion-derived nanoparticles from a cell-free oxidative potency assay and metabolic activa-tion of organic compounds. Environ. Health Perspect., 2009, 117, 54-60.
109. Oberdörster, G.; Oberdörster, E.; Oberdörster, J. Nanotoxicology: an emerg-ing discipline evolving from studies of ultrafine particles. Environ. Health Perspect., 2005, 113, 823-839.
110. Kreuter, J.; Shamenkov, D.; Petrov, V.; Ramge, P.; Cychutek, K.; Koch-Brandt, C.; Alyautdin, R. Apolipoprotein-mediated transport of nanoparticle- bound drugs across the blood-brain barrier. J. Drug Target., 2002, 10, 317-325.
111. Tian, F.; Cui, D.; Schwarz, H.; Estrada, G.; Kobayashic, H. Cytotoxicity of single wall carbon nanotubes on human fibroblasts. Toxicol. In Vitro, 2006, 20, 1202-1211.
112. Kreyling, W.G.; Möller, W.; Semmler-Behnke, M.; Oberdörster, G. In: Particle Toxicology, Donaldson, K., Borm, P., Ed.; Boca Raton, CRC Press: Taylor and Francis Group, 2007, 47-74.
113. Kreyling, W.G.; Geiser, M. In: Nanoparticles in Medicine and Environment, Inhalation and Health Effects, J.C Marijnissen, L, Gradon, Ed.; Springer Berlin, 2009, 138-176.
114. Kreyling, W.G.; Semmler-Behnke, M.; Moller, W. Ultrafine Particle-Lung Interactions: Does Size Matter? J. Aerosol Med., 2006, 19, 74-83.
115. Ahn, C.H.; Chae, S.Y.; Bae, Y.H. Biodegradable poly(ethylenimine) for plasmid DNA delivery. J. Control. Release, 2002, 80, 273-282.
116. Oupicky, D.; Ogris, M.; Howard, K.A. Importance of lateral and steric stabi-lization of polyelectrolyte gene delivery vectors for extended systemic circulation. Mol. Ther., 2002, 5, 463-472.
117. Park, Y.; Kwok, K.Y.; Boukarim, C. Synthesis of sulfhydryl cross-linking poly(ethylene glycol)-peptides and glycopeptides as carriers for gene delivery. Bioconjug. Chem., 2002, 13, 232-239.
118. Maratos-Flier, E.; Kao, C.Y.; Verdin, E.M.; King, G.L. Receptor-mediated vectorial transcytosis of epidermal growth factor by Madin-Darby canine kidney cells. J. Cell Biol., 1987, 105, 1595-1601.
119. Ikeda, E.; Takubo, K.; Kodama, T.; Okada, Y. Brain-Specific Expression of Vascular Endothelial Growth Factor 146 Correlates with the Blood-Brain Barrier Induction in Quail Embryos. Dev. Neurosci., 2008, 30, 331-339.
120. Deguchi, Y.; Okutsu, H.; Okura, T.; Yamada, S.; Kimura, R.; Yuge, T.; Furukawa, A.; Morimoto, K.; Tachikawa, M.; Ohtsuki, S. Internalization of basic fibroblast growth factor at the mouse blood-brain barrier involves perlecan, a heparan sulfate proteoglycan. J. Neurochem., 2002, 83, 381-389.
121. Reinhardt, R.R.; Bondy, C.A. Insulin-like growth factors cross the blood-brain barrier. Endocrinology, 1994, 135, 1753-1761.
122. Townsend, S.A.; Evrony, G.D.; Gu, F.X.; Schulz, M.P.; Brown, R.H.; Langer, R. Tetanus toxin C fragment-conjugated nanoparticles for targeted drug delivery to neurons. Biomaterials, 2007, 28, 5176-5184.
123. King, G.L.; Johnson, S.M. Receptor-mediated transport of insulin across endothelial cells. Science, 1985, 227, 1583-1586.
124. Witt, K.A.; Huber, J.D.; Egleton, R.D.; Davis, T.P. Insulin Enhancement of Opioid Peptide Transport across the Blood-Brain Barrier and Assessment of Analgesic Effect. J. Pharmacol. Exp. Ther., 2000, 295, 972-978.
125. Pardridge, W.M.; Triguero, D.; Buciak, J.; Yang, J. Evaluation of cationized rat albumin as a potential blood-brain barrier drug transport vector. J. Pharmacol. Exp. Ther., 1990, 255, 893-899.
126. Lu, W.; Zhang, Y.; Tan, Y.Z.; Hu, K.L.; Jiang, X.G.; Fu, S.K. Cationic albumin conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J. Control. Release, 2005, 107, 428-448.
127. Lu, W.; Tan, Y.Z.; Hu, K.L.; Jiang, X.G. Cationic albumin conjugated pegy-lated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier. Int. J. Pharmaceut., 2005, 295, 247-260.
128. Pan, W.; Barron, M.; Hsuchou, H.; Tu, H.; Kastin, A.J. Increased Leptin Permeation across the Blood-Brain Barrier after Chronic Alcohol Ingestion. Neuropsychopharmacology, 2007, 33, 859-866.
129. Banks, W.A.; DiPalma, C.R.; Farrell, C.L. Impaired transport of leptin across the blood-brain barrier in obesity: relationship to plasma levels and adiposity in humans. Peptides, 1999, 20, 1341-1345.
130. Hu, K.; Li, J.; Shen, Y.; Lu, W.; Gao, X.; Zhang, Q.; Jiang, X. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: In vitro and in vivo evaluations. J. Control. Release, 2009, 134, 55-61.
131. Fillebeen, C.; Descamps, L.; Dehouck, M.P.; Fenart, L.; Benaissa, M.; Spik, G.; Cecchelli, R.; Pierce, A. Receptor-mediated Transcytosis of Lactoferrin through the Blood-Brain Barrier. J. Biol. Chem., 1999, 274, 7011-7017.
132. Karkan, D.; Pfeifer, C.; Vitalis, T.Z.; Arthur, G.; Ujiie, M.; Chen, Q.; Tsai, S.; Koliatis, G.; Gabathuler, R.; Jefferies, W.A. A Unique Carrier for Delivery of Therapeutic Compounds beyond the Blood-Brain Barrier. PLoS One, 2008, 3, e2469.
133. Roberts, R.L.; Fine, R.E.; Sandra, A. Receptor-mediated endocytosis of transferrin at the blood-brain barrier. J. Cell Sci., 1993, 104, 521-532.
134. Ulbrich, K.; Hekmatara, T.; Herbert, E.; Kreuter, J. Transferrin- and transferring receptor- antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur. J. Pharmaceut. Biopharmaceut., 2009, 71, 251-256.
135. Demeule, M.; Currie, J.C.; Bertrand, Y.; Christian, Ch.; Nguyen, T.; Gina, A.; Gabathuler, R.; Castaigne, J.P.; Liveau, R. Involvement of the low- density lipoprotein receptor-related protein in the transcytosis of the brain de-livery vector Angiopep-2. J. Neurochem., 2008, 106, 1534-1544.
136. Mortensen, L.J.; Oberdörster, G.; Pentland, A.P.; DeLouise, L.A. In vivo Skin Penetration of Quantum Dot nanoparticles in the Murine Model: The Effect of UVR. Nano Lett., 2008, 8, 2779-2787.
137. Berry C.C. Intracellular delivery of nanoparticles via the HIV-1 TAT pep-tide. Nanomedicine, 2008, 3, 357-365.
138. Fuente, J.M.; Berry, C.C. Tat peptide as an efficient molecule to translocate gold nanoparticles into the cell nucleus. Bioconjug. Chem., 2005, 16, 1176-1180.
139. Rao, K.S.; Reddy, M.K.; Horning, J.L.; Labhasetwar, V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials, 2008, 29, 4429-4438.
140. Scherrmann, J.M.; Temsamani, J. The use of Pep: Trans vectors for the delivery of drugs into the central nervous system. Int. Congr. Ser., 2005, 1277, 199-211.
141. Semmler-Behnke, M.; Kreyling, W.G.; Lipka, J.; Fertsch, S.; Wenk, A.; Takenaka, S.; Schmid, G.; Brandau, W. Biodistribution of 1.4- and 18-nm Gold Particles in Rats. Small, 2008, 4, 2108-2111.
142. Alyautdin, R.; Gothier, D.; Petrov, V. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cya- noacrylate) nanoparticles. J. Pharmaceut. Biopharmaceut., 1995, 41, 44-48.
143. Schroeder, U.; Sommerfeld, P.; Ulrich, S.; Sabel, B.A. Nanoparticle technol-ogy for delivery of drugs across the blood-brain barrier. J. Pharm. Sci., 1998, 87, 1305-1307.
144. Gulyaev, A.E.; Gelperina, S.E.; Skidan, I.N. Significant transport of doxoru-bicin into the brain with polysorbate 80-coated nanoparticles. Pharmaceut. Res., 1999, 16, 1564-1569.
145. Kreuter, J. Application of nanoparticles for the delivery of drugs to the brain. Int. Congr. Ser., 2005, 1277, 85-94.
146. Gelperina, S.E.; Khalansky, A.S.; Skidan, I.N.; Smirnova, Z.S.; Bobruskin, A.I.; Severin, S.E.; Turowski, B.; Zanella, F.E.; Kreuter, J. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacry-late) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol. Lett., 2002, 126, 131-141.
147. Friese, A.; Seiller, E.; Quack, G.; Lorenz, B.; Kreuter, J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled re-lease system. Eur. J. Pharmaceut. Biopharmaceut., 2000, 49, 103-109.
148. Alyautdin, R.N.; Tezikov, E.B.; Ramge, P.; Kharkevich, D.A.; Begley, D.J.; Kreuter, J. Significant entry of tubocurarine into the brain of rats by adsorption topolysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brainperfusion study. J. Microencapsul., 1998, 15, 67-74.
149. Calvo, P.; Gouritin, B.; Brigger, I.; Lasmezas, C.; Deslys J.P.; Williams, A.; Andreux, J.P.; Dormont, D.; Couvreur, P. PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases. J. Neurosci. Methods, 2001, 111, 151-155.
150. Wilson, B.; Samanta, M.K.; Santhi, K.; Kumar, K.P.S.; Paramakrishnan, N.; Suresh, B. Targeted delivery of tacrine into the brain with polysorbate 80- coated poly(n-butylcyanoacrylate) nanoparticles. Eur. J. Pharmaceut. Bio- pharmaceut., 2008, 70, 75-84.
151. Wilson, B.; Samanta, M.K.; Santhi, K.; Kumar, K.P.S.; Paramakrishnan, N.; Suresh, B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res., 2008, 1200, 159-168.
152. Pereverzeva, E.; Treschalin, I.; Bodyagin, D.; Maksimenko, O.; Kreuter, J.; Gelperina, S. Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats. Toxicol. Lett., 2008, 178, 9-19.
153. Couvreur, P.; Kante, B.; Grislain, L.; Roland, M.; Speiser, P. Toxicity of polyalkylcyanoacrylate nanoparticles II: Doxorubicin-loaded nanoparticles. J. Pharmaceut. Sci., 1982, 71, 790-792.
154. Blasi, P.; Giovagnoli, S.; Schoubben, A.; Ricci, M.; Rossi, C. Solid lipid nanoparticles for targeted brain drug delivery. Adv. Drug Deliv. Rev., 2007, 59, 454-477.
155. Wong, H.L.; Bendayan, R.; Rauth, A.M.; Li, Y.; Wu, X.Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev., 2007, 59, 491-504.
156. Date, A.A.; Joshi, M.D.; Patravale, V.B. Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv. Drug Deliv. Rev., 2007, 59, 505-521.
157. Bhaskar, S.; Tian, F.; Stoeger, T.; Kreyling, W.; Fuente, J.M.; Grazú, V.; Borm, P.; Estrada, G.; Ntziachristos, V.; Razansky, D. Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part. Fibre Toxicol., 2010, 7, 1-25.
158. Schwarze, S.R.; Dowdy, S.F. In vivo protein transduction: Intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol. Sci., 2000, 21, 45-48.
159. Liu, L.; Guo, K.; Lu, J.; Venkatraman, S.S.; Luo, D.; Nag, K.C., Ling, E.A.; Moochhala, S.; Yang, Y.Y. Biologically active core/shell nanoparticles self- assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials, 2008, 29, 1509-1517.
160. Agyare, E.K.; Curran, G.L.; Ramakrisham, M.; Yu, C.C.; Poduslo, J.F.; Kandimalla, K.K. Development of a smart nano-vehicle to target cerebrovas- cular amyloid deposits and brain parenchymal plaques observed in Alz-heimer's disease and cerebral amyloid angiopathy. Pharm. Res., 2008, 25, 2674-2684.
161. Josephson, L.; Tung C.H.; Moore, A.; Weissleder, R. High-efficiency intra-cellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug. Chem., 1999, 10, 186-191.
162. Santra, S.; Yang, H.; Dutta, D.; Stanley, J.T.; Holloway, P.H.; Tan, W.; Moudgil, B.M.; Mericle, R.A. TAT conjugated, FITC doped silica nanoparticles for bioimaging applications. Chem. Commun. (Camb), 2004, 24, 2810-2811.
163. Stroh, M.; Zimmer, J.P.; Duda, D.G.; Levchenko, T.S.; Cohen, K.S.; Brown, E.B.; Scadden, D.T.; Torchilin, V.P.; Bawendi, M.G.; Fukumura, D.; Jain, R.K. Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat. Med., 2005, 11, 678-682.
164. Jeang, K.T.; Xiao, H.; Rich, E.A. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J. Biol. Chem., 1999, 274, 28837-28840.
165. Vives, E.; Brodin, P.; Lebleu, B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem., 1997, 272, 16010-16017.
166. Weeks, K.M.; Ampe, C.; Schultz, S.C.; Steitz, T.A.; Crothers, D.M. Frag-ments of the HIV-1 Tat protein specifically bind TAR RNA. Science, 1990, 249, 1281-1285.
167. Ruben, S.; Perkins, A.; Purcell, R.; Joung, K.; Sia, R.; Burghoff, R.; Haseltine, W.A.; Rosen, C.A. Structural and functional characterization of human immunodeficiency virus tat protein. J. Virol., 1989, 63, 1-8.
168. Park, J.; Ryu, J.; Kim, K.A.; Lee, H.J.; Bahn, J.H.; Han, K.; Choi, E.Y.; Lee, K.S.; Kwon, H.Y.; Choi, S.Y. Mutational analysis of a human immunodeficiency virus type 1 Tat protein transduction domain which is required for de-livery of an exogenous protein into mammalian cells. J. Gen. Virol., 2002,83, 1173-1181.
169. Schwarze, S.R.; Hruska, K.A.; Dowdy, S.F. Protein transduction: Unre-stricted delivery into all cells. Trends Cell Biol., 2000, 10, 290-295.
170. Derossi, D.; Joliot, A.H.; Chassaing, G.; Prochiantz, A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem., 1994, 269, 10444-10450.
171. Fischer, P.M.; Zhelev, N.Z.; Wang, S.; Melville, J.E.; Fåhraeus, R.; Lane, D.P. Structure-activity relationship of truncated and substituted analogues of the intracellular delivery vector penetratin. J. Pept. Res., 2000, 55, 163-172.
172. Drin, G.; Déméné, H.; Temsamani, J.; Brasseur, R. Translocation of the pAntp peptide and its amphipathic analogue AP-2AL. Biochemistry, 2001, 40, 1824-1834.
173. Letoha, T.; Gaál, S.; Somlai, C.; Venkei, Z.; Glavinas, H.; Kusz, E.; Duda, E.; Czajlik, A.; Peták, F.; Penke, B. Investigation of penetratin peptides. Part 2. In vitro uptake of penetratin and two of its derivatives. J. Pept. Sci., 2005, 11, 805-811.
174. Christiaens, B.; Grooten, J.; Reusens, M.; Joliot, A.; Goethals, M.; Vandek-Erckhove, J.; Prochiantz, A.; Rosseneu, M. Membrane interaction and cellular internalization of penetratin peptides. Eur. J. Biochem., 2004, 271, 1187-1197.
175. Letoha, T.; Gaál, S.; Somlai, C.; Czajlik, A.; Perczel, A.; Penke, B. Mem-brane translocation of penetratin and its derivatives in different cell lines. J. Mol. Recognit., 2003, 16, 272-279.
176. Fischer, R.; Waizenegger, T.; Köhler, K.; Brock, R. A quantitative validation of fluorophore-labelled cell-permeable peptide conjugates: Fluorophore and cargo dependence of import. Biochem. Biophys. Acta., 2002, 1564, 365-374.
177. Nakase, I.; Niwa, M.; Takeuchi, T.; Sonomura, K.; Kawabata, N.; Koike, Y.; Takehashi, M.; Tanaka, S.; Ueda, K.; Simpson, J.C.; Jones, A.T.; Sugiura, Y.; Futaki, S. Cellular uptake of arginine-rich peptides: Roles for macropino-cytosis and actin rearrangement. Mol. Ther., 2004, 10, 1011-1022.
178. Dupont, E.; Prochiantz, A.; Joliot, A. In: Handbook of cell penetrating pep-tides; Langel, U., Ed.; Taylor & Francis Group, LLC, 2006; pp. 5-28.
179. Rousselle, C.; Clair, P.; Lefauconnier, J.M.; Kaczorek, M.; Scherrmann, J.M.; Temsamani, J. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol. Pharma-col., 2000, 57, 679-686.
180. Bolton, S.J.; Jones, D.N.; Darker, J.G.; Eggleston, D.S.; Hunter, A.J.; Walsh, F.S. Cellular uptake and spread of the cell-permeable peptide penetratin in adult rat brain. Eur. J. Neurosci., 2000, 12, 2847-2855.
181. Pooga, M.; Hällbrinka, M.; Zorkoa, M.; Langela, U. Cell penetration by transportan. FASEB J., 1998, 12, 67-77.
182. Pooga, M.; Kut, C.; Kihmark, M.; Hallbrink, M.; Fernaeus, S.; Raid, R.; Land, T.; Hallberg, E.; Bartfai, T.; Langl, U. Cellular translocation of proteins by transportan. FASEB J., 2001, 15, 1451-1453.
183. Pooga, M.; Padari, K.; Langel, U. In: Handbook of cell penetrating peptides; Langel, U., Ed.; Taylor & Francis Group, LLC, 2006; pp. 183-200.
184. Saalik, P.; Elmquist, A.; Hansen, M.; Padari, K.; Saar, K.; Viht, K.; Langel, U.; Pooga, M. Protein cargo delivery properties of cell-penetrating peptides. A comparative study. Bioconjug. Chem., 2004, 15, 1246-1253.
185. Drin, G.; Cottin, S.; Blanc, E.; Rees, A.R.; Temsamani J. Studies on the internalization mechanism of cationic cell-penetrating peptides. J. Biol. Chem., 2003, 278, 31192-31201.
186. Padari, K.; Säälik, P.; Hansen, M.; Koppel, K.; Raid, R.; Langel, U.; Pooga, M. Cell transduction pathways of transportans. Bioconjug. Chem., 2005, 16, 1399-1410.
187. Futaki, S.; Suzuki, T.; Ohashi, W.; Yagami, T.; Tanaka, S.; Ueda, K.; Sugi-ura, Y. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem., 2001, 276, 5836-5340.
188. Mitchell, D.J.; Kim, D.T.; Steinman, L.; Fathman, C.G.; Rothbard, J.B. Polyarginine enters cells more efficiently than other polycationic ho-mopolymers. J. Pept. Res., 2000, 56, 318-325.
189. Wender, P.A.; Mitchell, D.J.; Pattabiraman, K.; Pelkey, E.T.; Steinman, L.; Rothbard, J.B. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. USA, 2000, 97, 13003-13008.
190. Kumar, P.; Wu, H.; McBride, J.L.; Jung, K.E.; Kim, M.H.; Davidson, B.L.; Lee, S.K.; Shankar, P.; Manjunath, N. Transvascular delivery of small interfering RNA to the central nervous system. Nature, 2007, 448, 33-40.
191. Schwarze, S.R.; Ho, A.; Vocero-Akbani, A.; Dowdy, S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science, 1999, 285, 1569-1572.
192. Temsamani, J.; Rousselle, C.; Rees, A.R.; Scherrmann, J.M. Vector mediated drug delivery to the brain. Expert Opin. Biol. Ther., 2001, 1, 773-782.
193. Abbott, N.J.; Romero, I.A. Transporting therapeutics across the blood-brain barrier. Mol. Med. Today, 1996, 2, 106-113.
194. Tamai, I.; Tsuji, A. Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci., 2000, 89, 1371-1388.
195. Smith, Q.R. Drug delivery to brain and the role of carrier mediated transport. Adv Exp. Med. Biol., 1993, 331, 83-93.
196. Mena, I.; Cotizias, G.C. Protein intake and treatment of Parkinson's disease with levodopa. N. Engl. J. Med., 1975, 292, 181-184.
197. Cornford, E.M.; Young, D.; Paxton, J.W.; Finlay, G.J.; Wilson W.R.; Pardridge, W.M. Melphalan penetration of the blood-brain barrier via the neutral amino acid transporter in tumor-bearing brain. Cancer Res., 1992, 52, 138-143.
198. Markovitz, D.C.; Fernstrom, J.D. Diet and uptake of aldomet by the brain: Competition with natural large neutral amino acids. Science, 1977, 197, 1014-1015.
199. Uchino, H.; Kanai, Y.; Kim do, K.; Wempe, M.F.; Chairoungdua, A.; Mori-moto, E.; Anders, M.W.; Endou, H. Transport of amino acid-related compounds mediated by L-type amino acid transporter1 (LAT1): Insights into the mechanisms of substrate recognition. Mol. Pharmacol., 2002, 61, 729-737.
200. Duffy, K.R.; Pardridge, W.M. Blood-brain barrier transcytosis of insulin and developing rabbits. Brain Res., 1987, 420, 32-38.
201. Moos, T.; Morgan, E.H. Transferrin and transferrin receptor function in brain barrier systems. Cell. Mol. Neurobiol., 2000, 20, 77-79.
202. Pardridge, W.M.; Eisnberg, J.; Yang, J. Human blood-brain barrier transfer-rin receptor. Metabolism, 1987, 36, 892-895.
203. Dehouck, B.; Fenart, L.; Dehouck, M.P.; Pierce, A.; Torpier, G.; Cecchelli, R. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J. Cell Biol., 1997, 138, 877-889.
204. Bjorbaek, C.; Elmquist, J.K.; Michl, P.; Ahima, R.S.; van Buren, A. Expres-sion of leptin receptor isoforms in rat brain microvessels. Endocrinology, 1998, 139, 3485-3491.
205. Duffy, K.R.; Pardridge, W.M.; Rosenfeld, R.G. Human blood-brain barrier insulin like growth factor receptor. Metabolism, 1988, 37, 136-140.
206. Bickel, U.; Yoshikawa, T.; Landaw, E.M.; Faull, K.F.; Pardridge, W.M. Pharmacologic effects in vivo in brain by vector-mediated peptide drug de-livery. Proc. Natl. Acad. Sci. USA, 1993, 90, 2618-2622.
207. Pardridge, W.M.; Kang, Y.S.; Buciak, J.L.; Yang, J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood- brain barrier in vivo in the primate. Pharm. Res., 1995, 12, 807-816.
208. Pardridge, W.M. Non-invasive drug delivery to the human brain using en-dogenous blood - brain barrier transport system. Pharmacol. Sci. Technol. Today, 1999, 2, 49-59.
209. Pardridge, W.M.; Kang, Y.S.; Buciak, J.L. Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat BBB in vivo using vector-mediated peptide drug delivery. Pharm. Res., 1994, 11, 738-746.